14

Jan2020
W. Neil Palmer In its December 2019 NEWSletter[1], the Patented Medicine Prices Review Board (PMPRB) is “reminding” patentees that they are required under the Patent Act (the Act) and the Patented Medicines Regulations (the Regulations) to file all zero-dollar sales, referring specifically to free goods. This “reminder” is troubling ... Read More

18

Dec2019

26

Nov2019
REGISTRATION IS OPEN! Learn how the new PMPRB amendments and guidelines will affect your pharmaceutical pricing, negotiations and reimbursement Join PDCI Market Access Inc., Canada’s leading pricing and reimbursement consultancy, for industry-only sessions on the pricing guidelines, led by senior members ... Read More

21

Nov2019
Pricing changes for Canada’s patented medicines are on their way and stakeholders are anticipating the release of the updated guidelines. How will the guidelines be operationalized? How will the new pharmacoeconomic factors be implemented? In an effort to answer these questions, PDCI has attempted to reverse-engineer the proposed Pharmacoeconomic Value ... Read More

31

Oct2019
3Sixty Public Affairs and PDCI Market Access have collaborated to create an infographic that unmasks the reality behind the assumptions Health Canada has used to justify its ongoing drug pricing reforms (through the Patented Medicine Prices Review Board). When it comes to federal drug pricing reform in Canada, there is ... Read More

25

Oct2019
PDCI is very pleased to welcome Keeley Farrell to the PDCI Team as Analyst, HTA and Clinical Evaluation. Keeley will help to support the development and preparation of the evidence-based clinical components of reimbursement and pricing submissions. She will also conduct research to support market access and ... Read More

22

Oct2019
PDCI presented a case study on the proposed amendments to the PMPRB regulations in Canada at the 2019 CAPT Conference held by the Canadian Association for Population Therapeutics. The objective of this policy analysis was to estimate the impact of the proposed PMPRB amendments on orphan drug prices. Review our poster ... Read More

12

Sep2019
REGISTRATION IS OPEN! Learn how the new PMPRB amendments and guidelines will affect your pharmaceutical pricing, negotiations and reimbursement Join PDCI Market Access Inc., Canada’s leading pricing and reimbursement consultancy, for industry-only sessions on the pricing guidelines, led by senior members of the PDCI team ... Read More

28

Aug2019

04

Jul2019
PDCI Market Access Inc. is pleased to announce a new Strategic Partnership with Goeree Consulting Ltd (owned and operated by Ron Goeree). Goeree Consulting and PDCI are bringing together an exceptional level of experience and expertise in health economics, while further expanding ... Read More